ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation-Reference-Cited by-同舟云学术

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation

Published:2018-02-02 Issue:5 Volume:32 Page:1070-1080
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Malcikova J.,Tausch E.,Rossi D.,Sutton L. A.,Soussi T.^ORCID,Zenz T.,Kater A. P.,Niemann C. U.,Gonzalez D.,Davi F.,Gonzalez Diaz M.,Moreno C.,Gaidano G.,Stamatopoulos K.,Rosenquist R.,Stilgenbauer S.,Ghia P.^ORCID,Pospisilova S.,

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-017-0007-7.pdf

Reference55 articles.

1. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164–74.

2. Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Döhner K, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123:3247–54.

3. Fischer K, Cramer P, Busch R, Böttcher S, Bahlo J, Schubert J, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30:3209–16.

4. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–56.

5. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–6.

Cited by 163 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic lymphocytic leukemia with MDM2 amplification as an alternative pathway to TP53 dysfunction;Leukemia & Lymphoma;2024-09-04

2. Medical history and lifestyle factors have limited impact on time‐to‐first‐treatment in patients with chronic lymphocytic leukemia;eJHaem;2024-08-27

3. Applications of Nanopore sequencing in precision cancer medicine;International Journal of Cancer;2024-07-19

4. Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities;HemaSphere;2024-07

5. The incidence of TP53 mutations in patients with chronic lymphocytic leukemia in Iran;Asian Journal of Oncology;2024-06-25